Summary: In 10,584 patients with type 2 diabetes and chronic kidney disease, sotagliflozin reduced the total of cardiovascular deaths, heart failure hospitalisations and urgent heart failure visits compared with placebo (5.6 vs 7.5 events per 100 patient-years; hazard ratio 0.74; 95% CI 0.63 to 0.88) over a median of 16 months. The primary endpoint was changed during the trial, which ended early after loss of funding.
PICO Summary
| Element | Detail |
|---|---|
| Population | 10,584 patients with type 2 diabetes (HbA1c 7% or above), chronic kidney disease (eGFR 25 to 60 mL/min/1.73 m²) and cardiovascular risk factors, with or without albuminuria; multicentre, double-blind, randomised, placebo-controlled trial; median follow-up 16 months. |
| Intervention | Sotagliflozin (n=5292). |
| Comparison | Placebo (n=5292). |
| Outcome | Total cardiovascular deaths, heart failure hospitalisations and urgent visits for heart failure: 5.6 vs 7.5 events per 100 patient-years; HR 0.74 (95% CI 0.63 to 0.88); p<0.001. Cardiovascular death: 2.2 vs 2.4 per 100 patient-years; HR 0.90 (95% CI 0.73 to 1.12); p=0.35. Original co-primary endpoints: first cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, HR 0.84 (95% CI 0.72 to 0.99); first cardiovascular death or heart failure hospitalisation, HR 0.77 (95% CI 0.66 to 0.91). Diarrhoea, genital mycotic infections, volume depletion and diabetic ketoacidosis were more common with sotagliflozin. |
Expert Commentary
My verdict is cautiously positive. In 10,584 patients with type 2 diabetes and an eGFR of 25 to 60, sotagliflozin lowered the total of cardiovascular deaths, heart failure hospitalisations and urgent heart failure visits (5.6 against 7.5 events per 100 patient-years; hazard ratio 0.74; 95% CI 0.63 to 0.88). The direction agrees with the rest of the class, and the trial enrolled patients with and without albuminuria. The limitation that matters is how the result was reached. The primary endpoint was changed during the trial, and the trial ended early after loss of funding, at a median of 16 months. A result obtained on a revised endpoint in a shortened trial deserves less weight than the hazard ratio alone suggests. Cardiovascular death was not reduced (hazard ratio 0.90; 95% CI 0.73 to 1.12), and diarrhoea, genital mycotic infections, volume depletion and diabetic ketoacidosis were all more common with the drug. Funding came from the manufacturers. Can I use this with my patients? The trial supports the use of this class in diabetic kidney disease at an eGFR down to 25, mainly to prevent heart failure events. I would want a completed trial with a prespecified endpoint and full follow-up before treating the size of the effect as settled.
References
Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129-139. doi:10.1056/NEJMoa2030186. PMID: 33200891.

